tetano
Editor, Senior Moderator
Biomedicines
. 2021 Feb 1;9(2):133.
doi: 10.3390/biomedicines9020133.
A Strategy to Elicit M2e-Specific Antibodies Using a Recombinant H7N9 Live Attenuated Influenza Vaccine Expressing Multiple M2e Tandem Repeats
Daria Mezhenskaya[SUP] 1 [/SUP], Irina Isakova-Sivak[SUP] 1 [/SUP], Tatiana Kotomina[SUP] 1 [/SUP], Victoria Matyushenko[SUP] 1 [/SUP], Min-Chul Kim[SUP] 2 [/SUP], Noopur Bhatnagar[SUP] 2 [/SUP], Ki-Hye Kim[SUP] 2 [/SUP], Sang-Moo Kang[SUP] 2 [/SUP], Larisa Rudenko[SUP] 1 [/SUP]
Affiliations
Abstract
Influenza viruses remain a serious public health problem. Vaccination is the most effective way to prevent the disease; however, seasonal influenza vaccines demonstrate low or no effectiveness against antigenically drifted and newly emerged influenza viruses. Different strategies of eliciting immune responses against conserved parts of various influenza virus proteins are being developed worldwide. We constructed a universal live attenuated influenza vaccine (LAIV) candidate with enhanced breadth of protection by modifying H7N9 LAIV by incorporating four epitopes of M2 protein extracellular part into its hemagglutinin molecule. The new recombinant H7N9+4M2e vaccine induced anti-M2e antibody responses and demonstrated increased protection against heterosubtypic challenge viruses in direct and serum passive protection studies, compared to the classical H7N9 LAIV. The results of our study suggest that the H7N9+4M2e warrants further investigation in pre-clinical and phase 1 clinical trials.
Keywords: ADCC; CDC; IgG; M2e antigen; cross-protection; influenza; live attenuated influenza vaccine; mouse model; recombinant influenza virus; universal influenza vaccine.
. 2021 Feb 1;9(2):133.
doi: 10.3390/biomedicines9020133.
A Strategy to Elicit M2e-Specific Antibodies Using a Recombinant H7N9 Live Attenuated Influenza Vaccine Expressing Multiple M2e Tandem Repeats
Daria Mezhenskaya[SUP] 1 [/SUP], Irina Isakova-Sivak[SUP] 1 [/SUP], Tatiana Kotomina[SUP] 1 [/SUP], Victoria Matyushenko[SUP] 1 [/SUP], Min-Chul Kim[SUP] 2 [/SUP], Noopur Bhatnagar[SUP] 2 [/SUP], Ki-Hye Kim[SUP] 2 [/SUP], Sang-Moo Kang[SUP] 2 [/SUP], Larisa Rudenko[SUP] 1 [/SUP]
Affiliations
- PMID: 33535408
- DOI: 10.3390/biomedicines9020133
Abstract
Influenza viruses remain a serious public health problem. Vaccination is the most effective way to prevent the disease; however, seasonal influenza vaccines demonstrate low or no effectiveness against antigenically drifted and newly emerged influenza viruses. Different strategies of eliciting immune responses against conserved parts of various influenza virus proteins are being developed worldwide. We constructed a universal live attenuated influenza vaccine (LAIV) candidate with enhanced breadth of protection by modifying H7N9 LAIV by incorporating four epitopes of M2 protein extracellular part into its hemagglutinin molecule. The new recombinant H7N9+4M2e vaccine induced anti-M2e antibody responses and demonstrated increased protection against heterosubtypic challenge viruses in direct and serum passive protection studies, compared to the classical H7N9 LAIV. The results of our study suggest that the H7N9+4M2e warrants further investigation in pre-clinical and phase 1 clinical trials.
Keywords: ADCC; CDC; IgG; M2e antigen; cross-protection; influenza; live attenuated influenza vaccine; mouse model; recombinant influenza virus; universal influenza vaccine.